TB Prevention

The World Health Organization (WHO) has introduced new development targets for long-acting injectable medicines that could make tuberculosis (TB) prevention and treatment easier in the future. The proposed approach aims to reduce the need for months of daily medication, potentially helping patients manage treatment with fewer healthcare visits.

Published on October 28, 2026, the new guidance sets out the characteristics that future injectable treatments should achieve. WHO’s goals include delivering a complete course of preventive treatment through a single injection and developing treatments for active TB that last no more than four months, with three or fewer dosing visits. These are targets for medicine developers, not newly approved treatments available for routine patient care.

What Has WHO Announced?

The new guidance focuses on long-acting injectables, commonly referred to as LAIs. These medicines are designed to release their active ingredients over an extended period, potentially reducing how frequently patients need to take medication.

WHO has outlined two main objectives. For TB prevention, the ideal future regimen would provide the entire preventive treatment course through one injection during a single healthcare visit. For people with active TB disease, the target is a treatment regimen lasting four months or less and requiring no more than three dosing encounters.

The organisation has also specified that these treatments should be safe and effective at least to the same standard as existing oral regimens. They should ideally be deliverable by trained healthcare workers at the lowest feasible level of the health system, without requiring a cold chain for storage and transport.

Why Is TB Treatment Difficult for Some Patients?

Tuberculosis is an infectious disease caused by bacteria that most often affect the lungs, although other parts of the body can also be affected. It spreads through the air when a person with infectious TB releases bacteria, for example, by coughing.

Treatment requires the correct medicines to be taken according to a prescribed schedule. Depending on the type of TB and the medicines used, treatment may continue for several months. Some patients face difficulties maintaining this routine because of medicine-related side effects, travel expenses, work commitments or distance from healthcare facilities.

Interrupting or stopping treatment without medical advice can lead to poor outcomes and, in some cases, contribute to drug resistance. Long-acting injections could reduce the number of occasions on which patients must take medicines or travel to a healthcare facility. However, they would not eliminate the need for diagnosis, medical supervision and follow-up care.

What Could This Mean for India?

The development is particularly relevant to India, which has one of the world's largest TB burdens. Delivering effective treatment to large and diverse populations remains a major public health challenge, especially where patients face financial or geographical barriers to accessing care.

If safe and affordable long-acting medicines are developed, they could eventually make treatment easier for some patients. Fewer dosing visits could reduce transport costs and the time people spend away from work or family responsibilities. A simpler regimen might also help health services manage treatment delivery more efficiently.

However, these potential benefits depend on several factors. The medicines must prove effective in clinical trials, receive the necessary regulatory approvals and become affordable enough for public health programmes to use widely. Their introduction would also require suitable training, monitoring and reliable supply systems.

New Injections Are Still Under Development

WHO's announcement does not mean patients can currently replace their prescribed TB medicines with a single injection. The organisation has published target regimen profiles to guide researchers, pharmaceutical companies and product developers as they work on future treatments.

Several long-acting candidates for TB are entering or approaching clinical development, but their safety and effectiveness must be established before they can be adopted for routine care. WHO's targets are intended to help developers focus on treatments that meet patients' needs without compromising the quality of care.

The guidance also recognises that injections will not suit everyone. WHO says research into improved oral treatments should continue alongside injectable development, preserving patient choice when future treatment options become available.

What Happens Next?

The next stage will involve research and development, followed by clinical testing and regulatory assessment of potential medicines. Their success will depend not only on how long they remain active in the body, but also on safety, effectiveness, cost, ease of administration and accessibility in different healthcare settings.

If successful, long-acting injectable regimens could eventually reduce some of the practical difficulties associated with TB prevention and treatment. For patients, that could mean fewer medication-taking occasions and fewer clinic visits. For health systems, it could offer new ways to deliver care to communities facing barriers to regular treatment.

For now, existing treatment guidance remains in place. Patients should continue taking prescribed medicines and consult their healthcare providers before making any changes.

The bottom line: WHO is encouraging the development of simpler TB treatments, including a possible single-injection preventive course and shorter injectable regimens for active disease. These goals offer a promising direction for future research, but new medicines must first demonstrate that they are safe, effective and accessible.